Idiopathic pulmonary fibrosis (IPF) is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The cause of IPF is unknown, and currently there is no FDA approved treatment. IPF occurs primarily in people 50 to 70 years of age. Based on the published scientific literature, median survival time from diagnosis is two to five years in patients with IPF, and most patients die from the complications associated with the disease. We believe that there are approximately 100,000 patients with IPF in the United States, approximately two-thirds of whom have mild to moderate disease severity.

InterMune has the latest stage compound currently in development for the treatment of IPF. Enrollment for CAPACITY, the Phase 3 program evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, was completed in May 2007.

View our IPF animation (Windows Media format) Video use courtesy of Coalition for Pulmonary Fibrosis.

Investigational, not approved by the FDA.